Second Expert Webinar organized together with Takeda

Takeda offered an expert webinar on “Future horizons in MPS II: a quest for valid clinical and biochemical endpoints*”

If you missed the live event broadcasted on October 20, you can see the webcast of this very interesting EXPERT WEBINAR organized together with TAKEDA using this LINK. Please note that the webcast is offered in English, Russian, Spanish & Portuguese, so you can choose your prefered language!

PROGRAM

Welcome and introduction
Professor Joseph Muenzer
University of North Carolina at Chapel Hill 

Neuronopathic MPS II: where are we now?
Professor Joseph Muenzer
University of North Carolina at Chapel Hill 

Challenges in assessing cognition and behavior in patients with MPS II
Professor Elsa Shapiro
University of Minnesota

A role for biomarkers in MPS II
Professor Maria Fuller
University of Adelaide

Faculty Q&A
Concluding remarks

We hope this has helped the MPS community stay up to date on industry developments & news!

This meeting is initiated, funded and developed by Takeda.
Copyright 2020 Takeda Pharmaceutical Company Limited. All rights reserved.
Takeda and the Takeda Logo are registered trademarks of Takeda Pharmaceutical Company Limited.

2020-10-21 00:00:00

First Expert Webinar organized with ABEONA Therapeutics

Abeona has offered an expert webinar on “GENE THERAPY CLINICAL TRIALS FOR MUCOPOLYSACCHARIDOSIS (MPS) TYPES IIIA AND IIIB*”

Given the current situation that has forced to move the MPS International Symposium to the summer of 2021, and the cancellation of many annual MPS Meetings at national level, we wanted to offer a platform to facilitate knowledge sharing and information regarding news and developments on MPS and related diseases.

 Thus, we are pleased to present the first EXPERT WEBINAR organized together with ABEONA THERAPEUTICS, which took place on July 23 and featured simultaneous translation into Spanish, Mandarin Chinese and Japanese. If you could not attend the live webcast, you can watch it now following this LINK.

PROGRAM

About Abeona
João Siffert, M.D.
CEO Abeona Therapeutics

MPS Pathophysiology & Gene Therapy MOA
Kevin Flanigan, M.D.
Director, Center for Gene Therapy at Nationwide Children’s Hospital, Professor of Pediatrics and Endowed Chair in Neuromuscular Research Ohio State
Investigator for the Transpher A study, Transpher B study

MPS IIIA Natural-History Data Studies
Maria Escolar, M.D., M.S.
Director, Program for the Study of Neurodevelopment in Rare Disorders and Professor of Pediatrics, University of Pittsburgh
Investigator for the Transpher A study, study ABT-003

Study Results to Date (last presented at ASGCT 2020)
Kevin Flanigan, M.D.

Study Overview
Maria Escolar, M.D., M.S.

Q&A Session

We hope this will help the MPS community stay up to date on industry developments & news!

*Abeona Therapeutics sponsored studies. Search “mucopolysaccharidosis” at ClinicalTrials.gov for full study listing. Brought to you by the International MPS Society and Abeona.

2020-07-30 00:00:00